Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
ConclusionsThis large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Denmark Health | Drugs & Pharmacology | Heart | Heart Attack | Overactive Bladder | Overactive Bladder Syndrome | Stroke | Study | Sweden Health | Women